BeiGene
BGNE
#881
Rank
NZ$35.84 B
Marketcap
$326.49
Share price
1.71%
Change (1 day)
0.44%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total liabilities

Total liabilities on the balance sheet as of June 2024 : NZ$3.79 B

According to BeiGene 's latest financial reports the company's total liabilities are NZ$3.79 B. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

BeiGene - Total liabilities on balance sheet (from 2014 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31NZ$3.58 B14.08%
2022-12-31NZ$3.14 B-10.4%
2021-12-31NZ$3.50 B45.74%
2020-12-31NZ$2.40 B156.19%
2019-12-31NZ$0.93 B27.14%
2018-12-31NZ$0.73 B44.92%
2017-12-31NZ$0.51 B567.82%
2016-12-31NZ$76.37 M23.02%
2015-12-31NZ$62.08 M74.86%
2014-12-31NZ$35.5 M-42.28%
2013-12-31NZ$61.51 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
NZ$19.65 M-99.48%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$0.94 B-75.08%๐Ÿ‡บ๐Ÿ‡ธ USA